HOW MANY BOTTLES OF JUBLIA WOULD YOUR PATIENT REQUIRE (APPROXIMATELY)?

Please consult the Product Monograph for full dosage and administration information.

JUBLIA is indicated for the topical treatment of mild to moderate onychomycosis (tinea unguium) of toenails without lunula involvement due to Trichophyton rubrum and Trichophyton mentagrophytes in immunocompetent adult patients.

Clinical use:

• Safety and efficacy in patients under 18 or over 75 have not been studied.
• Greater sensitivity of some older individuals (≥65) cannot be ruled out.

Contraindications:

Hypersensitivity to efinaconazole or any excipients of JUBLIA or container component.

Relevant warnings and precautions:

• Patients with a history or clinical signs of immunosuppression, HIV infection, uncontrolled diabetes, other toenail infection except Candida, toenail infection to the matrix, only lateral toenail disease, severe plantar tinea pedis.
• Concomitant use of other antifungal therapy and daily use of JUBLIA for more than 48 weeks.
• For topical use only, and only on toenails and immediately adjacent skin.
• Flammable – keep away from heat or flame.
• Sensitivity reaction or severe irritation.
• Pregnant and nursing women.

For more information:

Please consult the Product Monograph here for important information relating to adverse reactions, interactions, and dosing information, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-361-4261.

References:

1. JUBLIA Product Monograph.
2. Bausch Health, Canada Inc. Data on file. 2020.